Pharmaceutical formulation in India: patent-rich, startup-light

What it is

Pharmaceutical formulation is the science of designing drug compositions that deliver active pharmaceutical ingredients (APIs) safely and effectively. It selects excipients and determines the dosage form—tablet, injectable, cream, inhaler—to optimize bioavailability, stability, and patient compliance.

The process balances molecular properties with patient-centric design. Preformulation studies characterize the API, then formulators choose excipients and a manufacturing route. The goal is a finished product that hits its therapeutic target while meeting regulatory standards, often using modeling techniques like artificial neural networks to fine-tune variables.

The value chain

• Upstream: API and excipient sourcing from chemical and natural-product suppliers.
• Core R&D: Preformulation and formulation development—characterizing API properties, excipient compatibility, and designing the dosage form and process. This stage concentrates IP and defensibility.
• Midstream: Manufacturing and scale-up, from pilot batches to commercial production. Process know-how and quality-by-design create high barriers.
• Downstream: Packaging, labeling, distribution, and dispensing to wholesalers, pharmacies, and patients. Margins thin here; value lies in cold-chain or specialty handling.
• Outsourced formulation development (CDMO market) is a growing segment, valued at $37.3 billion globally in 2024 (Grand View Research).

Where it's heading

Global trends push formulation toward patient-centric, specialty dosage forms and away from pure generics. India, already the world’s largest generic supplier (~20% of global demand), is projected to be the fastest-growing drug formulation market at a 6.5% CAGR through 2036 (Future Market Insights).

• Patient-centric designs: orally disintegrating tablets, long-acting injectables, and pediatric-friendly forms gain traction (Patheon).
• CDMO reliance grows as biologics and complex generics demand specialized formulation capabilities (Grand View Research).
• Shift from volume generics to innovative therapies and biosimilars, with Indian pharma exports targeted to reach nearly $350 billion by 2047 (Bain & Company).
• AI and digital tools increasingly optimize formulation variables and process development, cutting trial time (Bain & Company).
• Government schemes like PLI and PMBJP incentivize domestic manufacturing and R&D in pharmaceuticals (Department of Pharmaceuticals).

The opportunity in India

Our data maps 256 patents to pharmaceutical formulation, yet only 30 patent-holding startups appear—and many are individual inventors or incubators, not commercial ventures. Just six deep-tech companies in our dataset explicitly reference formulation in their profile, suggesting a wide gap between patent activity and startup formation.

The white space is in building formulation-focused deep-tech ventures that leverage India’s generics backbone for novel delivery systems, AI-driven design, or complex dosage forms. With the broader health-life-sciences sector attracting $2.6 billion across 973 funded companies, capital exists, but formulation-specific startups remain rare. The patent stock signals latent technical depth waiting for entrepreneurial translation.

India signal: patents, startups, capital

Patents mapped to pharmaceutical formulation total 256. Momentum is indeterminate because India’s ~18-month confidentiality window understates recent filings—do not read this as a decline.

Thirty patent-holding startups appear in our data. The top holder is Chitkara Innovation Incubator Foundation (7 patents). Others include Axxelent Pharma Science, Ayur Biopharma, and several individual inventors like Abhimanyu Singh Rathore and Amit Sharma, each with a single patent. These are early-stage signals, not yet a dense startup cluster.

Only six companies in our dataset explicitly reference pharmaceutical formulation in their profile: JSL Health Sciences (Hyderabad), Auxillion Lifecare (Ahmedabad), Seidecosaa Biotech (Bengaluru Urban), Theraxcel Healthcare (Dakshina Kannada), Savikalpa Sciences (New Delhi), and Greots Lifesciences (Mumbai). The broader ecosystem likely contains more firms that don’t use this exact phrasing.

Sector-level funding in health-life-sciences is robust: 973 companies raised $2,575.2 million, with a median round of $1.0 million. Notable funded players in the sector include Enveda ($517M), Qure.ai ($130M), and Atonarp ($111M), though these are not formulation-specific. Formulation-focused venture funding remains scarce in our data.

In our data

Sources

• Pharmaceutical Formulation Development: Principles & Process ↗
• The art and science of drug formulation | Article ↗
• Pharmaceutical Formulation - an overview ↗
• Understanding the pharmaceutical value chain ↗
• A comprehensive guide to the pharmaceutical supply chain ↗
• Pharma Supply Chain: A Comprehensive Guide ↗
• Pharmaceutical Market Size, Share and Trends 2026 to 2035 ↗
• Formulation Development Outsourcing Market (2025 - 2030) ↗